The 2nd pilot using the HTA Core Model for Rapid Relative Effectiveness Assessment
Assessment is now available. The technology assessed is renal denervation systems for treatment-resistant hypertension.
From the EUNetHTA site:
“The intervention involves the destruction of efferent sympathetic nerves and afferent nerves within the wall of the renal arteries to reduce sympathetic nerve traffic, thereby causing a reduction in blood pressure. It is intended for people with persistent blood pressure "≥ 140/90 mm Hg" despite using at least 3 antihypertensive drugs in adequate doses, including a diuretic.
Several renal denervation systems that are available on the European market were identified. The level of existent evidence varies between the different technologies. In most studies, safety and the effect on blood pressure have been investigated. Additional studies and results will be available in coming years.”
